Deal-Making Trends
2020 Could Spell The End Of Mega-Mergers, For Now
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
The Only Way Is Nasdaq – Part One
The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.
Investing In People: Aligning VCs And Today’s Entrepreneurs
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Creating Stability In A Time Of Transition
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
Deals
Latest From Deals
Deals In Depth: October 2020
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.
Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies
Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.
Deals Shaping The Medical Industry, October 2020
This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.
Intense Transactional Activity Continues To Propel Biopharma Growth
Outcome Capital analyzed transactional activity by the largest biopharmaceutical companies in the three-and-a-half-year period between January 2017 and June 2020 to reveal development and therapeutic areas trends.
Dealmaking Quarterly Statistics, Q3 2020
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
Financing Quarterly Statistics, Q3 2020
During Q3, biopharmas brought in an aggregate $36.6bn in financing and device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.